The NDSU Department of Pharmaceutical Sciences has invited Dr. Ruiwen Zhang to deliver a research lecture, “Targeting MDM2 Oncogene for Cancer Therapy: A story beyond P53,” scheduled for Thursday, Sept. 18, from 11 a.m. to 12:15 p.m. in Sudro Hall Room 21.
Zhang obtained his medical degree and doctorate in toxicology and Occupational epidemiology from Shanghai Medical University, China. He completed his post-doctoral/clinical pharmacology fellowship at University of Alabama School of Medicine and then joined the school’s faculty in 1992 and advanced to cancer pharmacology laboratory director. In 2010, he joined Texas Tech University Health Sciences Center School of Pharmacy as tenured professor and chair.
Zhang has been invited to give more than 130 presentations for prestigious universities, institutions and organizations. He has published more than 190 papers, two books, more than 50 invited reviews/book chapters and more than 150 meeting abstracts. Zhang’s publications have been cited more than 7,400 times.
He is a certified toxicologist by the American Board of Toxicology and served on board of directors of the organization from 2009-13. He has been an FDA advisory committee member since 2003 and served as a study section member for National Institutes of Health, Department of Defense, Centers for Disease Control, Food and Drug Administration and other international panels. Zhang was elected as a fellow of American Association for the Advancement of Science in 2009.
The seminar is open to all persons interested in biomedical research. For further information, contact Jagdish Singh at 701-231-7943.
NDSU is recognized as one of the nation's top 108 public and private universities by the Carnegie Commission on Higher Education.